ANI Pharmaceuticals (NASDAQ:ANIP) Issues Earnings Results

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) issued its earnings results on Friday. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts' consensus estimates of $1.41 by $0.22, RTT News reports. The business had revenue of $190.60 million during the quarter, compared to analyst estimates of $175.36 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. ANI Pharmaceuticals's revenue was up 44.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.04 earnings per share. ANI Pharmaceuticals updated its FY25 guidance to $6.12-6.49 EPS.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock traded up $0.67 during trading hours on Tuesday, hitting $59.13. 230,425 shares of the company's stock were exchanged, compared to its average volume of 215,984. The stock's 50-day moving average is $57.32 and its 200-day moving average is $58.11. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -107.51 and a beta of 0.74. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $70.81.

Insider Transactions at ANI Pharmaceuticals

In related news, CFO Stephen P. Carey sold 7,500 shares of the firm's stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now owns 154,468 shares in the company, valued at $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the senior vice president now owns 49,059 shares in the company, valued at approximately $2,943,540. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,300 shares of company stock worth $584,009. Insiders own 12.70% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of research analysts recently commented on the company. StockNews.com lowered ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday. Leerink Partners began coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price objective for the company. Leerink Partnrs upgraded ANI Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, December 11th. Finally, HC Wainwright reiterated a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.